Emactuzumab

DRUG7 trials

Sponsors

Synox Therapeutics Limited, Hoffmann-La Roche, M.D. Anderson Cancer Center, SynOx Therapeutics Limited

Conditions

CancerFallopian Tube AdenocarcinomaFallopian Tube Clear Cell AdenocarcinomaFallopian Tube Endometrioid AdenocarcinomaFallopian Tube Mucinous AdenocarcinomaFallopian Tube Serous AdenocarcinomaFallopian Tube Transitional Cell CarcinomaFallopian Tube Undifferentiated Carcinoma

Phase 1

A Study of Emactuzumab and Atezolizumab Administered in Combination in Participants With Advanced Solid Tumors

CompletedNCT02323191

Hoffmann-La RocheSolid Cancers

Start: 2015-01-19End: 2020-08-21Updated: 2020-08-27

A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors

CompletedNCT02760797

Hoffmann-La RocheNeoplasms

Start: 2016-05-09End: 2018-04-06Updated: 2018-05-22

A Study of Atezolizumab in Combination With an Immunotherapy Agent Investigated With or Without Anti-Cd20 Therapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

WithdrawnNCT03369964

Hoffmann-La RocheLymphoma, Non-Hodgkin

Start: 2018-03-14End: 2019-08-31Updated: 2018-04-05

Phase 2

Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

TerminatedNCT02923739

M.D. Anderson Cancer CenterFallopian Tube Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma +17

Start: 2017-05-05End: 2022-09-27Updated: 2024-03-13

Phase 3

A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study

Active, not recruitingNCT03768063

Hoffmann-La RocheCancer

Start: 2019-02-28End: 2028-07-05Target: 1000Updated: 2026-07-24

Study of Emactuzumab for Tenosynovial Giant Cell Tumor (TGCT)

Active, not recruitingNCT05417789

SynOx Therapeutics LimitedTGCT

Start: 2024-10-09End: 2030-09-30Target: 128Updated: 2026-07-29

A Phase III, Multicentre, Randomised, Double-Blind Study to Assess the Safety and Efficacy of Emactuzumab vs. Placebo in Subjects with Tenosynovial Giant Cell Tumour

Active, not recruitingCTIS2023-510422-32-00

Synox Therapeutics LimitedTenosynovial Giant Cell Tumour

Start: 2024-09-10Target: 93Updated: 2025-12-01

Related Papers

TANGENT study design: a phase III, randomized study of emactuzumab for the treatment of tenosynovial giant cell tumors

Future Oncology2026-07-20

A phase 3, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of emactuzumab in patients with tenosynovial giant cell tumor (TANGENT).

Journal of Clinical Oncology2025-05-28

Phase Ib/II Study of Lacnotuzumab in Combination with Spartalizumab in Patients with Advanced Malignancies

Journal of Immunotherapy and Precision Oncology2023-11-249 citations

Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade

Journal for ImmunoTherapy of Cancer2022-05-0192 citations

Phase Ib study of anti-CSF-1R antibody emactuzumab in combination with CD40 agonist selicrelumab in advanced solid tumor patients

Journal for ImmunoTherapy of Cancer2020-10-0172 citations

Phase I study of RG7155, a novel anti-CSF1R antibody, in patients with advanced/metastatic solid tumors.

Journal of Clinical Oncology2015-05-2033 citations